Drug search by name

Lorcaserin Extended-Release Tablets and Breast cancer

Result of checking the interaction of drug Lorcaserin Extended-Release Tablets and disease Breast cancer for safety when used together.

Check result:

Lorcaserin Extended-Release Tablets <> Breast cancer

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Lorcaserin can cause elevations in prolactin. In clinical trials of at least one year duration, elevations of prolactin greater than the upper limit of normal, two times the upper limit of normal, and five times the upper limit of normal occurred in 6.7%, 1.7%, and 0.1% of lorcaserin-treated patients, compared to 4.8%, 0.8%, and 0.0% of placebo-treated patients, respectively. One patient treated with lorcaserin developed a prolactinoma. Based on in vitro data, approximately one-third of human breast cancers are thought to be prolactin-dependent. The clinical significance of this observation with respect to long-term lorcaserin therapy is unknown. Chronic administration of other prolactin-stimulating drugs (e.g., neuroleptics, phenothiazines) has been associated with mammary tumorigenesis in rodent studies but not in human clinical or epidemiologic studies. Until further data are available, therapy with lorcaserin should be administered cautiously in patients with a previously detected breast cancer.

Lorcaserin Extended-Release Tablets

Generic Name: lorcaserin

Brand Name: Belviq, Belviq XR

Synonyms: Lorcaserin

What is Lorcaserin Extended-Release Tablets?